Red Flags: How to Spot Unsafe Online GLP-1 Sellers

GLP-1 medicines are among the most in-demand prescriptions in the country, and they are expensive. That combination has created a crowded online marketplace: legitimate telehealth services and pharmacies on one side, and on the other, websites, social media accounts and messaging-app sellers offering the same drug names with no prescription, rock-bottom prices or “research only” labels.

From the outside, the two can look surprisingly similar. This guide explains the warning signs that regulators and researchers have documented, how to check a pharmacy and a prescriber in a few minutes, and what to do if something you received doesn’t look right.

Educational only. This is not medical advice and does not endorse or rate any company. Decisions about GLP-1 treatment should be made with a licensed clinician who knows your health history.

The short answer

A safe source of a GLP-1 medicine has three things you can verify: a licensed clinician who screens you and writes a prescription, a state-licensed pharmacy that fills it, and a way to reach a professional after the medicine arrives. Remove any one of those and the risk rises sharply.

The clearest red flags are sellers that:

• ship without a screening or prescription,
• say a compounded drug is “the same as” an FDA-approved one,
• sell products labeled “for research use only” or “not for human consumption,”
• offer prices or bulk deals that seem too good to be true,
• ask for payment by cryptocurrency, wire, or peer-to-peer apps only, or
• send medicine that arrives warm, damaged, mislabeled or looking different from what you were shown.

If you see one of these, stop before you pay. If you see several, walk away.

Why this matters more for GLP-1s than for most medicines

Most GLP-1 weight-management medicines are injected under the skin, and the injectable forms need refrigeration. That raises the stakes: a contaminated or wrongly dosed injectable can cause harm that a contaminated pill might not, and a product that sat warm in a delivery truck may not work as intended.

The World Health Organization put it plainly in its 2024 alert on falsified semaglutide pens: falsified products may lead to ineffective treatment because of an incorrect dose, contamination with harmful substances, or unknown or substituted ingredients, and because they are injected, they “could be life-threatening.” WHO also noted that a falsified pen could contain another undeclared active ingredient, such as insulin. Its surveillance system has seen increasing reports of falsified semaglutide in all regions of the world since 2022.

Fakes are not only an online problem. WHO’s alert covered three falsified batches of a brand-name semaglutide pen found in Brazil, the UK and the US, all detected in the regulated supply chain. FDA has also said it is aware of counterfeit semaglutide pens marketed in the US. But buying from unverified websites with no prescription is the route where the risks pile up fastest.

What researchers found when they bought GLP-1s online

The best direct evidence comes from a team of researchers in Hungary and the US who did what a shopper might do: they searched Google and Bing, then tried to buy semaglutide without a prescription.

In their market survey, published in the Journal of Medical Internet Research in 2024, they reviewed 1,080 search-result links. Of the 317 links that led to online pharmacies, 134 (about 42%) pointed to 59 different illegal pharmacy websites. Web-traffic data suggested that the top 30 domains linked to illegal pharmacies drew an estimated 4.7 million visits over three months in 2023. Nearly a third of the illegal sites listed no address or contact information at all.

The researchers then placed test orders with six of these sites, which had already been classified as rogue or not recommended by website-verification services. Their results, published as a research letter in JAMA Network Open, are summarized below.

What they checked	What they found
Prescription or health questions before purchase	None of the six sellers asked for either
Delivery	3 of 6 orders (all for brand-name pens) never arrived; the sellers demanded extra “customs” payments of $650 to $1,200
Packaging inspection	Delivered vials met only 8 or 9 of 22 checklist criteria, versus 22 of 22 for a genuine product
Purity	About 7% to 14%, versus 99% claimed on the label
Amount of drug	29% to 39% more semaglutide than labeled
Contamination	Endotoxin (bacterial residue) detected; one sample notably elevated; no live microbes found at testing
Payment	4 of the 6 sellers accepted cryptocurrency

Two of the sites the team studied later received FDA warning letters. The study was small and excluded higher-priced sellers, so it can’t tell us how common each problem is. What it does show is the pattern: no screening, unreliable delivery, and products whose contents didn’t match their labels.

FDA’s red flags, explained

FDA keeps a list of warning signs for consumers buying GLP-1s through websites and telehealth platforms. Here is what each one means in practice.

1. No screening or prescription by a licensed clinician

A real prescription requires a clinician to review your health history, medicines and goals, and to be willing to say no. FDA lists “does not require a screening and prescription by a licensed doctor” as a red flag, and its online-pharmacy guidance says a safe pharmacy “always requires a doctor’s prescription.” NABP, the association of state pharmacy boards, reports that 96% of the illegal online pharmacies it reviewed did not require a valid prescription.

Watch for subtler versions too: a “consultation” that is a single checkbox, an approval that arrives seconds after you pay, or no questions about conditions such as a personal or family history of medullary thyroid cancer, pancreatitis or pregnancy. Our guide on how to get a GLP-1 prescription explains what a proper assessment usually covers.

2. Claims that a compounded drug is “the same as” an approved one

Compounded medicines are made by pharmacies for individual patients. FDA says compounded drugs are not FDA-approved, so the agency does not review them for safety, effectiveness or quality before they are marketed. A seller that says its compounded product is “the same as,” “generic,” or “identical to” a brand-name drug is misleading you, and FDA names that claim as a warning sign.

A related tell, according to a compounding-pharmacy trade group quoted by NPR, is marketing that uses a brand name, such as “compounded Ozempic” or “compounded Mounjaro.” Legitimate compounders describe the active ingredient instead.

The legal backdrop has also changed. FDA declared the national shortages of tirzepatide and semaglutide injections resolved in December 2024 and February 2025, and as of its April 1, 2026 update, neither appears on FDA’s drug shortage list. FDA says compounded drugs should only be used when a patient’s medical needs can’t be met by an FDA-approved drug, and that pharmacies generally may not regularly make what are essentially copies of commercially available products unless a prescriber documents a significant clinical difference for that patient. Adding a vitamin to a near-copy does not automatically make it different. If a seller’s whole business is selling near-copies, ask why.

3. Prices that seem too good to be true

FDA and the BeSafeRx program both flag deep discounts as a warning sign. Brand-name GLP-1s have official self-pay programs with published prices, so a deal far below those, or a “today only” bulk offer, deserves suspicion. Our guides to semaglutide costs and tirzepatide costs explain what legitimate cash prices usually look like.

4. No licensed professional to answer questions afterward

Side effects such as nausea, constipation and dehydration are common during dose increases, and some symptoms need prompt medical attention. FDA lists “does not have a licensed doctor available to answer questions after you receive your medication” as a red flag. Safe pharmacies also have a licensed pharmacist available. If the only contact is a chat bot, a social media inbox or a messaging app, that’s a problem.

5. Medicine that looks wrong or arrives in poor condition

FDA’s warning signs include medicine that looks different from what you have received at a local pharmacy or what the website pictured, and packaging that is broken, damaged or missing instructions. FDA’s BeSafeRx list adds packaging in a foreign language, no expiration date, or an expired product. US Customs officials have made the same point in news coverage: a legitimate product shipped within the US should be labeled in English.

Temperature matters too. FDA has received complaints of compounded GLP-1s arriving warm or with inadequate ice packs, and recommends not using any injectable GLP-1 that arrives warm or without enough refrigeration.

For brand-name pens, WHO’s alert listed specific signs of falsified products, including a dose scale that extends out of the pen when you set the dose, a poor-quality label that doesn’t stick well, and spelling mistakes on the carton.

6. Spelling errors, wrong addresses or a pharmacy you can’t find

FDA is aware of fraudulent compounded semaglutide and tirzepatide with false labels. In some cases, the pharmacy named on the label doesn’t exist. In others, the label names a real licensed pharmacy that did not make the product. That’s why FDA lists label spelling errors, incorrect pharmacy addresses and pharmacy names you suspect are fraudulent as red flags, and why checking the pharmacy yourself, rather than trusting the label, matters.

“Research use only” products are not a loophole

Scroll social media for a few minutes and you’ll see sellers advertising semaglutide, tirzepatide and newer experimental compounds with a disclaimer such as “research use only” or “not for human consumption,” often alongside same-day shipping, discount codes and “certificates of analysis.” When we searched public posts on X in October 2026, accounts using exactly this language were posting several times a day.

FDA’s position is clear. It has warned companies that illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that were falsely labeled for research or not for human consumption, while actually being sold to consumers for human use with dosing instructions. FDA “urges consumers not to purchase these products which are of unknown quality and may be harmful to their health.”

Two more points worth knowing:

• Some of these compounds aren’t approved for anything. FDA says retatrutide and cagrilintide cannot be used in compounding under federal law, are not components of any FDA-approved drug, and have not been found safe and effective for any condition. FDA has warned telehealth companies for marketing retatrutide directly to consumers.
• A certificate of analysis is not a safeguard. It’s a document the seller provides. It doesn’t make a product legal for human use, and it can’t tell you how the product was stored or shipped. In the test-purchase study above, the labels on the delivered vials claimed 99% purity; the lab measured roughly 7% to 14%.

You can follow the science on medicines still in development in our Oral & New GLP-1s hub.

Fake ads, fake endorsements and payment traps

Many unsafe offers start with an ad rather than a pharmacy website. The Better Business Bureau has warned that scammers increasingly use deepfake videos and AI-generated images of celebrities, doctors and other trusted figures to promote GLP-1 medicines and weight-loss products. In one November 2025 warning, BBB said it had received 115 complaints and 172 scam reports about a supplement company whose celebrity endorsements its investigation found to be AI-generated fakes, with an average consumer loss of about $300.

Other patterns that come up repeatedly in consumer warnings and the research above:

• “Natural GLP-1” supplements, drops or patches. These are not prescription GLP-1 medicines. A real GLP-1 drug requires a prescription.
• Subscription traps. Sellers that lock you into repeated shipments or add charges you didn’t agree to. FDA’s BeSafeRx list includes “charges you for products you never ordered or received.”
• Payment only by crypto, wire, gift card or peer-to-peer apps. These are hard to reverse. Four of the six rogue sellers in the test-purchase study accepted cryptocurrency. Paying by credit card gives you more options to dispute a charge, though it does not make an unsafe seller safe.
• “Customs fee” requests after you’ve paid. All three non-delivery scams in the study followed this script.
• Vague privacy terms. BeSafeRx warns about sites that don’t clearly protect your personal and financial information or that sell it.

A 10-minute check before you pay

You don’t need special tools to screen a seller. These steps use free public databases.

Step	How to do it	What a good result looks like
1. Find the pharmacy’s name	Ask the service which pharmacy will fill your prescription, or check the site’s legal pages	A specific pharmacy name and a US street address
2. Check its license	Search your state board of pharmacy’s license database (FDA’s BeSafeRx page links to every state)	Listed and active in the state where you live. FDA says if it isn’t listed, don’t use it
3. Check the website	Enter the web address into NABP’s Safe Site Search at safe.pharmacy	Accredited, or at least not on the Not Recommended list. A web address ending in “.pharmacy” means NABP accredited the site
4. Check the prescriber	Ask for the clinician’s full name and credentials, then search your state’s medical, nursing or PA board, or the FSMB’s free DocInfo.org lookup for physicians	An active license in the state where you are located during the visit
5. Ask what you’ll receive	Is it an FDA-approved product or a compounded one? If compounded, why?	A clear answer, with a documented clinical reason for any compounded product
6. Ask about follow-up	How do you reach a clinician or pharmacist about side effects, and how fast do they respond?	A named way to reach a licensed professional, not just a sales chat

One caution about databases: in the market survey, more than half of the illegal websites the researchers found were not yet on NABP’s Not Recommended list, and about one in five weren’t listed in either verification database they checked, because rogue sites appear and disappear quickly. So “not on the bad list” is not the same as “verified.” The strongest signal is a positive one: the pharmacy is licensed in your state and the prescriber is licensed where you are.

A pharmacist interviewed in a YouTube explainer on compounded semaglutide made a related point: there’s no single standard formula for compounded GLP-1s, so each pharmacy decides what goes in the vial. That’s another reason to know exactly which pharmacy is involved and to talk through the choice with your prescriber.

For a broader look at how legitimate online programs work, see how telehealth weight-loss programs work and our comparison of telehealth vs in-person weight-loss care.

If you use a compounded product: extra safety points

If you and your prescriber decide a compounded GLP-1 is appropriate, FDA has highlighted several specific issues:

• Dosing errors. FDA has received reports of adverse events, some requiring hospitalization, linked to people measuring and injecting the wrong dose of compounded semaglutide, and in some cases to clinicians miscalculating doses. Make sure you understand the units on your syringe and the volume for each dose, and ask the pharmacist to walk you through it.
• Doses beyond the approved schedule. FDA has also received reports tied to compounded semaglutide or tirzepatide prescribed at higher doses, more frequent doses or faster dose increases than the approved labels describe. Serious nausea, vomiting, diarrhea, abdominal pain and constipation were among the reported problems.
• Multi-dose vials. FDA generally recommends discarding a multi-dose vial 28 days after first use, even if medicine remains and even if the compounder’s instructions say otherwise, and using a new sterile needle and syringe for every dose.
• Salt forms. FDA says salt forms such as semaglutide sodium and semaglutide acetate are different active ingredients from those in approved drugs, and it is not aware of any lawful basis for using them in compounding. Check the label and ask.

FDA notes that state-licensed pharmacies that are not outsourcing facilities aren’t required to report adverse events to FDA, so problems are likely underreported. Even so, as of May 31, 2026, FDA had received 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. FDA cautions that it isn’t always possible to tell whether the drug itself caused each event.

What to do if something seems wrong

If you haven’t paid yet: stop. Don’t send more money, especially “customs” or “release” fees.

If you received a product that looks wrong, arrived warm or damaged, or came from a seller you now doubt:

1. Don’t use it. Keep the product, packaging, label and receipts.
2. Contact the pharmacy and your prescriber. If you didn’t have a prescriber, contact your own doctor or a pharmacist.
3. Report quality problems or side effects to FDA MedWatch, online or by fax at 1-800-FDA-0178.
4. If you paid by card, contact your card issuer about disputing the charge.

If you already injected a product you’re unsure about and feel unwell, contact a clinician. Seek urgent care for severe or persistent abdominal pain (with or without vomiting), signs of dehydration such as dizziness or very little urine, symptoms of low blood sugar such as shakiness, sweating or confusion (especially if you also take insulin or a sulfonylurea), or signs of a serious allergic reaction. Our GLP-1 side effects hub explains which symptoms are common and which need attention, and our guide to GLP-1 nausea covers the most frequent one.

Safer ways to lower the cost

Price pressure is the main reason people end up on risky sites, so it’s worth knowing the legitimate options before you go looking for a bargain:

• Check your coverage first. Our guide on whether insurance covers GLP-1s for weight loss explains how to ask.
• Compare official self-pay prices for FDA-approved products, including lower-cost starting doses and pill options. See GLP-1 pills vs injections and our list of FDA-approved GLP-1s for weight loss.
• Ask your clinician whether another approved medicine, or a different dose, fits your situation and budget.

Our Costs Without Insurance hub collects these guides in one place.

The bottom line

Most of the danger in buying GLP-1s online comes from a small set of shortcuts: no prescription, no licensed pharmacy, no professional follow-up, and products sold under labels like “research use only” that dodge the rules for human medicines. Researchers who tested no-prescription semaglutide found non-delivery scams, misleading labels, low purity, too much drug per dose and signs of contamination.

The protection is simple and quick: verify the pharmacy with your state board and NABP, verify the prescriber with your state licensing board, insist on knowing exactly what you’ll receive and why, and never use an injectable that arrives warm, damaged or looking wrong. A service that welcomes those questions is a far better sign than one that promises a prescription in minutes.

Explore more in our Telehealth Weight Loss hub and the GLP-1 Guide.